The Return Of The “Specialty” Drug Pricing Debate In The US
Pharma has been almost wholly successful in shifting the ground in the US drug pricing debate away from high-cost “specialty” products and towards the large gap between list and net prices, with the most intense focus on older medicines like insulin. What happens when the debate shifts back?
You may also be interested in...
Plan includes new 30% manufacturer discount in the US Medicare Part D catastrophic phase, which manufacturers will oppose as too high. But it also caps beneficiary cost sharing, a long-sought industry goal.
The pharmaceutical industry and its strongest critics have long agreed on one thing: Medicare Part D would be improved if there was a cap on spending by beneficiaries. Now, there is an unlikely path that may make it surprisingly easy to get it done.
Medicare Payment Advisory Commission executive director Mathews suggests at April 30 hearing that manufacturers should bear more “liability” for catastrophic coverage in Medicare Part D.